Spots Global Cancer Trial Database for pdl1
Every month we try and update this database with for pdl1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | NCT02574598 | Carcinoma, Non-... | MK-3475 Docetaxel | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | NCT03725059 | Breast Cancer | Pembrolizumab (... Placebo (P) Paclitaxel (X) Doxorubicin (A) Epirubicin (E) Cyclophosphamid... Endocrine thera... Radiation thera... Surgery | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | NCT03099161 | Neoplasm | preladenant pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors | NCT04009460 | Solid Tumors Neoplasms Malignant Tumor | ES101 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | NCT02576977 | Multiple Myelom... | Pembrolizumab Pomalidomide Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | NCT02578680 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | NCT03302234 | Carcinoma, Non-... | Pembrolizumab Ipilimumab Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | NCT03407170 | Advanced Melano... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment | NCT04396223 | Gestational Tro... | Avelumab Inject... Methotrexate 1 ... | 18 Years - | Hospices Civils de Lyon | |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | NCT02220894 | Non-small Cell ... | pembrolizumab carboplatin paclitaxel pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | NCT03564691 | Neoplasms | MK-4830 Pembrolizumab Carboplatin Pemetrexed Lenvatinib Paclitaxel Cisplatin MK-4830A | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | NCT02143804 | Bladder Cancer High Grade Non Muscle Inva... | oncolytic adeno... | 18 Years - | CG Oncology, Inc. | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | NCT02578680 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | NCT02007070 | Non-small Cell ... | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | NCT04841538 | Thoracic Tumors Non-small Cell ... Small Cell Lung... | ES101 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | NCT02370498 | Gastric Adenoca... Gastroesophagea... | pembrolizumab paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | NCT02821000 | Melanoma | Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | NCT02775435 | Non-small Cell ... | Pembrolizumab Paclitaxel Nab-paclitaxel Carboplatin Saline placebo ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | NCT03950674 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | NCT02180061 | Melanoma | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients | NCT02574598 | Carcinoma, Non-... | MK-3475 Docetaxel | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | NCT03036488 | Triple Negative... | Pembrolizumab Carboplatin Paclitaxel Doxorubicin Epirubicin Cyclophosphamid... Placebo Granulocyte col... | 18 Years - | Merck Sharp & Dohme LLC | |
| CARE1 Pragmatic Clinical Trial | NCT06364631 | Metastatic Kidn... Metastatic Kidn... | Nivolumab Ipilimumab Pembrolizumab Cabozantinib Axitinib Lenvatinib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | NCT02542293 | Non Small Cell ... | Durvalumab +Tre... Paclitaxel + ca... Gemcitabine + c... Gemcitabine + c... Pemetrexed + ci... Pemetrexed + ca... | 18 Years - 130 Years | AstraZeneca | |
| Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | NCT02553499 | Advanced Solid ... | MK-1248 pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | NCT04776148 | Colorectal Neop... | pembrolizumab lenvatinib regorafenib TAS-102 (triflu... | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | NCT03062358 | Carcinoma, Hepa... | pembrolizumab placebo best supportive... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | NCT02007070 | Non-small Cell ... | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | NCT03515837 | Non-small Cell ... | pembrolizumab pemetrexed carboplatin cisplatin saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | NCT04841538 | Thoracic Tumors Non-small Cell ... Small Cell Lung... | ES101 | 18 Years - | Elpiscience Biopharma, Ltd. | |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | NCT03407170 | Advanced Melano... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | NCT01848834 | Cancer Solid Tumor | Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | NCT03665597 | Melanoma | Pembrolizumab D... Pembrolizumab D... Pembrolizumab D... Pembrolizumab D... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL | NCT03212807 | EBV Related Non... Primary CNS Lym... Primary Testicu... | Durvalumab Lenalidomide | 21 Years - 80 Years | Singapore General Hospital | |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | NCT03486873 | Solid Tumors Hematologic Mal... | Pembrolizumab Standard of Car... Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | NCT03515837 | Non-small Cell ... | pembrolizumab pemetrexed carboplatin cisplatin saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642 | Malignant Melan... | Atezolizumab Cobimetinib Vemurafenib | 18 Years - | Genentech, Inc. | |
| Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer | NCT02143804 | Bladder Cancer High Grade Non Muscle Inva... | oncolytic adeno... | 18 Years - | CG Oncology, Inc. | |
| Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | NCT02853331 | Renal Cell Carc... | Pembrolizumab Axitinib Sunitinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | NCT02775435 | Non-small Cell ... | Pembrolizumab Paclitaxel Nab-paclitaxel Carboplatin Saline placebo ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | NCT03833167 | Carcinoma, Squa... | Pembrolizumab 4... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | NCT02220894 | Non-small Cell ... | pembrolizumab carboplatin paclitaxel pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | NCT01953692 | Myelodysplastic... Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Primary Mediast... | Pembrolizumab Lenalidomide 20... Lenalidomide 25... | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | NCT03040999 | Head and Neck N... | Pembrolizumab Placebo Cisplatin Accelerated Fra... Standard Fracti... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | NCT02453594 | Hodgkin Lymphom... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | NCT03396445 | Pharmacokinetic... Solid Tumor Carcinoma, Non-... Triple Negative... | Boserolimab Pembrolizumab Pemetrexed Carboplatin Nab-paclitaxel | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
